Drug
Srp 1001 For
Srp 1001 For: highest development phase Phase 1/2, developed by Sarepta Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Sarepta Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| SRP-1001 for Injection NCT06131983 | Phase 1/2 | Muscular Dystrophy, Facioscapulohumeral |
Latest
No recent events.
Follow Srp 1001 For on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.